University of Minnesota. Driven to Discover.
A total of 62.4% of patients taking tafenoquine were free of P vivax after 6 months.
The vaccine "has the potential to save tens of thousands of children's lives."
Scientists are seeing high rates of treatment failure as they struggle to eliminate the disease in the region.
Get CIDRAP news and other free newsletters.
Sign up now»
Unrestricted financial support provided by
Grant support for ASP provided by
Become an underwriter»
CIDRAP - Center for Infectious Disease Research and PolicyOffice of the Vice President for Research, University of Minnesota, Minneapolis, MN
© 2020 Regents of the University of Minnesota. All rights reserved.The University of Minnesota is an equal opportunity educator and employer.